Home › Compound Library › Rimegepant (Nurtec ODT)

Rimegepant (Nurtec ODT)

CGRP Antagonistprescriptionoral · inferred

Small-molecule CGRP receptor antagonist ('gepant') orally disintegrating tablet approved for both acute migraine treatment and episodic migraine prevention (every other day). Plasma half-life ~11h. Oral bioavailability ~64%. No vasoconstrictive liability (unlike triptans), enabling use in patients with cardiovascular disease.

Projected serum levels — 75 mg, once daily

Rimegepant (Nurtec ODT)
Rimegepant (Nurtec ODT) modeled serum levels, 75 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Rimegepant (Nurtec ODT) modeled serum levels with a loading dose of 96.5 mg, then 75 mg once daily The first dose is larger so levels approach steady state faster. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 75 mg once daily (oral).

Loading schedule: 96.5 mg on day 1, then 75 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 56.2 mg, trough ≈ 13.8 mg body load. Population-based estimate over 15 days for a 75 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
CGRP Antagonist
Route modeled
Oral
Model confidence
inferred
Half-life
11 h
Common dose
75 mg
Suggested maximum
75 mg/day
Reference dose range
37.5–75 mg (single dose)
Suggested cadence
once daily
Validated against
75 mg oral — Cmax 1.2 mg/L at 1.5 h

Documented interactions

  • contraindicated
    Clarithromycin (Biaxin) + Rimegepant (Nurtec ODT) CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Rimegepant (Nurtec ODT) AUC by ~6.67x

  • contraindicated
    Diltiazem + Rimegepant (Nurtec ODT) CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Rimegepant (Nurtec ODT) AUC by ~6.67x

  • contraindicated
    Efavirenz (Sustiva) + Rimegepant (Nurtec ODT) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Rimegepant (Nurtec ODT) AUC by ~0.13x

  • contraindicated
    Grapefruit (whole fruit) + Rimegepant (Nurtec ODT) CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change Rimegepant (Nurtec ODT) AUC by ~6.67x

  • contraindicated
    Grapefruit Juice + Rimegepant (Nurtec ODT) CYP inhibition

    Grapefruit Juice mechanism_based of CYP3A4 predicted to change Rimegepant (Nurtec ODT) AUC by ~6.67x

  • contraindicated
    Paxlovid (Nirmatrelvir/Ritonavir) + Rimegepant (Nurtec ODT) CYP inhibition

    Paxlovid (Nirmatrelvir/Ritonavir) mechanism_based of CYP3A4 predicted to change Rimegepant (Nurtec ODT) AUC by ~6.67x

Serum checks 227 modeled interaction pairings for rimegepant (nurtec odt) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine Croop R et al. · Lancet, 2019 DOI

    Phase 3 trial demonstrating rimegepant 75 mg ODT efficacy for acute migraine across pain freedom and MBS endpoints.

  2. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine Lipton RB et al. · New England Journal of Medicine, 2019 DOI

    Pivotal trial establishing rimegepant's efficacy and safety profile in acute migraine, a non-triptan oral option without vasoconstriction.

2 published studies referenced in the app, each with a plain-language summary.